Haematological Cancer

The Haemato-oncology section provides genomic analysis of samples from patients with a range of haematological malignancies and lymphoproliferative conditions. The results obtained assist in diagnosis and classification, provide prognostic information for use in risk stratification, can direct therapeutic choice, and enable assessment of residual disease status post-treatment and/or post-transplant. We are a constituent laboratory of the West Midlands SIHMDS: MIRHO.

WMRGL provides testing commissioned by the NHS in England for the clinical indications listed in the Test Directory for haematological cancer and also accepts private referrals. Core commissioned testing is only available to patients from England who meet the defined eligibility criteria according to the Test Directory.

Specific information about accessing Whole Genome Sequencing in somatic cancer is available here.

Information on sample requirements and laboratory opening times can be found here, as can the MIRHO referral form for haematological cancer testing.

Test Information Sheets

AML     MDS     CML     MPN     CLL      WGS      Familial AML/MDS and ALL  

Service User Communications

March 2024 Changes to MPN testing pathways.pdf

November 2022 HO Test Turnaround Times [pdf]

May 2022 Haem Cancer WGS update letter and FAQs.pdf

November 2021 Changes to T cell clonality assessment at Southampton Mol Path Laboratory

May 2021 NPM1 MRD monitoring within the National Genomic Medicine Service.pdf

Oct 2020 Changes to the diagnostic MPN service [pdf]

Aug 2019 HO test turnaround times [pdf]

March 2018 CML reporting on IS [pdf]

March 2018 CML IS RQ results chart [pdf]